Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Glaukos's operating assets for the quarter that ended in Dec. 2023 was $645.0 Mil. Glaukos's operating liabilities for the quarter that ended in Dec. 2023 was $94.9 Mil. Glaukos's Total Assets for the quarter that ended in Sep. 2023 was $948.6 Mil. Therefore, Glaukos's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.58.
Glaukos Scaled Net Operating Assets Historical Data
The historical data trend for Glaukos's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Glaukos Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Scaled Net Operating Assets |
|
Get a 7-Day Free Trial
|
|
|
2.76 |
0.65 |
0.55 |
0.53 |
0.55 |
|
Glaukos Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Scaled Net Operating Assets |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.56 |
0.57 |
0.59 |
0.59 |
0.58 |
Competitive Comparison
For the Medical Devices subindustry, Glaukos's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glaukos Scaled Net Operating Assets Distribution
For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Glaukos's Scaled Net Operating Assets falls into.
Glaukos Scaled Net Operating Assets Calculation
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Glaukos's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (A: Dec. 2023 ) |
| = | (Operating Assets (A: Dec. 2023 ) | - | Operating Liabilities (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2022 ) |
| = | (644.983 | - | 94.91) | / | 1002.383 |
| = | 0.55 |
where
Glaukos's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (Q: Dec. 2023 ) |
| = | (Operating Assets (Q: Dec. 2023 ) | - | Operating Liabilities (Q: Dec. 2023 )) | / | Total Assets (Q: Sep. 2023 ) |
| = | (644.983 | - | 94.91) | / | 948.634 |
| = | 0.58 |
where
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glaukos (Glaukos) Business Description
Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.
Executives
| Alex R. Thurman |
officer: SVP & Chief Financial Officer |
C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672 |
| Joseph E Gilliam |
officer: CFO, SVP Corporate Development |
C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677 |
| Thomas William Burns |
director, 10 percent owner, officer: Chief Executive Officer |
C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653 |
| Marc Stapley |
director |
9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121 |
| Gilbert H Kliman |
director |
C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022 |
| Tomas Navratil |
officer: Chief Development Officer |
C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672 |
| Leana Wen |
director |
C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672 |
| Denice Torres |
director |
3 RABBIT RUN DRIVE, NEW HOPE PA 18938 |
| Chris M. Calcaterra |
officer: Chief Commercial Officer |
C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653 |
| Link William J Phd |
director, 10 percent owner |
ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
| Jonathan Silverstein |
director |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Orbimed Advisors Llc |
director |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Richard L Harrison |
officer: Treasurer, CFO & Secretary |
26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653 |
| Samuel D Isaly |
director |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Orbimed Capital Gp Iii Llc |
director |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Glaukos (Glaukos) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GKOS has been successfully added to your